Moleculent AB
64 employees on LinkedIn Β· 4 known investors
Moleculent develops biological discovery and disease understanding tools for scientists. The company focuses on decoding molecular foundations of biology to advance human health diagnostics and research.
Also known as Moleculent
Founders & leadership
Investors Β· 4
Also in the syndicate Β· 2
Funding
SEC filings, press & company announcements$26M disclosed across 1 of 4 rounds Β· 2024β2026
- $26MSeries AJun 2024 Β· 2 sourcesSource β
Source: company announcements and press reports β follow each round's link for the claim.
Company profile
researched Aug 2026Moleculent AB is a Stockholm, Sweden-headquartered life sciences technology company developing what it calls a functional profiling platform: a method to detect and profile cell-cell interactions directly within intact human tissue, rather than inferring them from gene or protein expression alone. The company positions this as an additional "functional layer" on top of existing spatial biology methods, which typically report where cells are located and what they express but do not directly measure receptor-ligand engagement between neighboring cells.
The platform is built on a proprietary Proximity Ligation Assay that detects cell-cell interactions in their native environment at high-plex, and in parallel performs cell typing through detection of individual proteins to supply tissue context. It is applied to clinical formalin-fixed paraffin-embedded (FFPE) tissue samples. Moleculent is also developing an automated instrument intended to make the workflow available to translational laboratories globally, with large-scale studies, high reproducibility and minimal hands-on time cited as design goals.
The initial application focus is immuno-oncology, using a T-cell oriented panel covering antigen presentation, immune checkpoints and cell type markers to profile interactions between cancer and immune cells in clinical samples. The company states the platform is designed to extend to other biological systems and disease areas over time.
Founding story
Olle Ericsson, PhD, is a co-founder and serves as Chief Executive Officer. Sources do not state a founding date. The leadership team is described as industry veterans who previously developed and commercialized life science tools at Halo Genomics (acquired by Agilent), Vanadis Diagnostics (acquired by PerkinElmer) and Spatial Transcriptomics (acquired by 10x Genomics).
Business model
Life science tools vendor: Moleculent is commercializing an assay-based platform and an automated instrument for research use, currently distributed to selected academic and biopharma partners through its Techstart Early Access Program ahead of a planned commercial launch.
Sources describe a pre-commercial-launch stage in which the platform is accessible through an early access program, with capital being deployed to drive the commercial launch of the instrument; specific pricing or revenue mechanics are not disclosed.
Traction
The company reported an oversubscribed $26M Series A in June 2024 and a further $20M round in April 2026, with management citing surging demand from research institutions and pharmaceutical partners in Europe and the US. Named early access partners include the University of Glasgow and Virginia Commonwealth University.
Latest developments
On 30 April 2026 Moleculent announced a $20 million financing led by Rubicon Healthcare Partners with participation from ARCH Venture Partners and Eir Ventures, appointed Ole Dahlberg to the Board of Directors, and announced expansion of the Techstart Early Access Program alongside plans for US commercial expansion and commercial launch of its automated instrument.
βΈFull profile β market position, technology, go-to-market, geography, history, risks & controversies
Market position
Moleculent describes itself as pioneering "functional profiling" and claims its platform is the first to measure cell-cell interactions in clinical tissue at scale, complementing existing spatial methods that often rely on inference of interactions. Its lead investor characterizes the platform as category-defining within the life sciences tools landscape.
The stated differentiator is direct measurement of receptor-ligand interactions between cells within intact tissue, versus spatial transcriptomics and other spatial methods that identify cell location and expression and infer interactions computationally.
Technology
The core technology is a proprietary multiplexed Proximity Ligation Assay that detects cell-cell interactions in situ at high-plex across many receptor-ligand pairs, combined with detection of individual proteins for cell typing and tissue context. It works on intact FFPE tissue. An automated instrument is under development to enable large-scale, reproducible studies with minimal hands-on time.
Go-to-market
Moleculent uses the Techstart Early Access Program, launched in November 2025 and expanded in 2026, to give selected translational researchers and biopharma partners priority access and pilot projects ahead of commercial launch. Applications to the program are accepted via the company website. Proceeds from the 2026 round are earmarked for expanding Techstart, building US commercial operations and launching the instrument commercially.
Academic and translational research groups, leading research institutions, and biopharmaceutical partners, initially in immuno-oncology; named early partners include the University of Glasgow (Prof. Nigel Jamieson) and Virginia Commonwealth University (Kevin Matthew Byrd).
Geography
Headquartered in Stockholm, Sweden, with activity and partners across Europe and the United States; the 2026 financing is intended to accelerate commercial operations in the US.
History
Moleculent AB emerged publicly in June 2024 with a $26 million Series A led by ARCH Venture Partners and co-led by Eir Ventures, at which point Patrick Weiss (ARCH) became Chairman and Sean Kendall (ARCH) and Magnus Persson (Eir Ventures) joined the board. In November 2025 the company launched its Techstart early access program for high-plex functional profiling of cell-cell interactions in FFPE tissue, initially targeting immuno-oncology. In April 2026 it closed a $20 million round led by Rubicon Healthcare Partners, adding Ole Dahlberg to the board and funding Techstart expansion, US commercial operations and the instrument's commercial launch.
Risks & controversies
No controversies are reported in the available sources. Sources indicate the instrument is still in development and the platform has not yet reached commercial launch, and no revenue, customer count or headcount figures are disclosed.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Competitors Β· 3
by search overlapCompanies competing with Moleculent AB for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline Β· 6
launches, deals, and filingsMoleculent announced expansion of its Techstart Early Access Program for academic and biopharma partners and acceleration of commercial operations in the United States, citing demand across Europe and the US.
Moleculent AB closed a $20 million financing round led by Rubicon Healthcare Partners with participation from ARCH Venture Partners, Eir Ventures and other existing investors. Proceeds fund expansion of the Techstart Early Access Program, commercial operations in the United States, and commercial launch of the instrument.
$20M source β
As part of the 2026 financing, Ole Dahlberg, Managing Partner at Rubicon Healthcare Partners, joined Moleculent's Board of Directors. He has over 20 years of life sciences management experience, including leadership roles at Life Technologies, Qiagen and Thermo Fisher Scientific (Cell Biology and Sample Preparation).
Moleculent launched Techstart, an early access program giving selected translational researchers access to its platform for high-plex functional profiling of cell-cell interactions in FFPE tissue samples, with an initial immuno-oncology focus and a T-cell panel covering antigen presentation, immune checkpoints and cell type markers.
Moleculent AB announced the closing of an oversubscribed $26 million Series A financing led by ARCH Venture Partners and co-led by Eir Ventures, with participation from existing investors. ARCH's Patrick Weiss was appointed Chairman; Sean Kendall (ARCH) and Magnus Persson (Eir Ventures) joined the Board of Directors.
$26M source β
Patrick Weiss of ARCH Venture Partners was appointed Chairman of the Board; Sean Kendall (ARCH Venture Partners) and Magnus Persson (Eir Ventures) joined the Board of Directors.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
βΈResearch sources Β· 8
primary sources listed
- Moleculent ABmoleculent.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Moleculent AB do?
- Stockholm-based life science tools company building a platform that maps cell-cell communication directly in human tissue.
- Who founded Moleculent AB?
- Moleculent AB was founded by Fredrik Roos.
- Who are Moleculent AB's investors?
- Moleculent AB's investors include ARCH Venture Partners, EIR Ventures.
- How much funding has Moleculent AB raised?
- Moleculent AB has disclosed $26M raised across 1 of its 4 known rounds.